New Enterprise Associates

News, insights, analysis and data

← Back to New Enterprise Associates profile

New Enterprise Associates related stories

All articles and analysis

  • peHUB Wire: Monday, September 20, 2010
    Brad Meikle- 20 September 2010

    Risky Business

  • Quote of the Day
    Connie Loizos- 17 September 2010

    "Some people are paying valuations that are completely absurd." --Scott Sandell, general partner with New Enterprise Associates, speaking with Forbes http://www.forbes.com/forbes/2010/0927/outfront-technology-private-company-shares-facebook-twitter.html on prices being paid on secondary markets, including for shares in companies that Sandell has backed.

  • peHUB Wire: Thursday, September 16, 2010
    Brad Meikle- 16 September 2010

    American Oligarchs?

  • peHUB Wire: Thursday, September 16, 2010
    Brad Meikle- 16 September 2010

    American Oligarchs?

  • Conviva Closes $15 Million Series C Funding Round
    VCJ Staff- 15 September 2010

    Conviva Inc. has closed a $15 million Series C round of funding. The San Mateo, Calif.-based provider of streaming solutions has raised a total of $44 million since its launch in 2006. GGV Capital led the financing round. Foundation Capital, New Enterprise Associates and Pelion Venture Partners are all returning investors.

  • Week in deals, Sept. 13, 2010
    Brad Meikle- 13 September 2010

    Summary of tech companies and other startups in North America that raised venture financing in the past week

  • Zyngenia Completes $15 million Series A Financing Extension
    VCJ Staff- 8 September 2010

    Zyngenia Inc., a Gaithersburg, Md.-based biotherapeutics company that is developing antibody drugs, completed a $15 million Series A financing extension from New Enterprise Associates.

  • Rhythm Pharmaceuticals Closes Series A Financing At $40 Million
    VCJ Staff- 8 September 2010

    Rhythm Pharmaceuticals completed its Series A financing at $40 million. The Boston, Mass.-based biotechnology company is developing therapies against metabolic diseases, such as diabetes. The round was led by MPM Capital and New Enterprise Associates. The two first held a first close on the Series A funding at $21 million earlier this year. Third Rock Ventures invested in Rhythm Pharmaceuticals. Lou Tartaglia, a partner at Third Rock, was named to Rhythm Pharmaceuticals’ board.

  • peHUB Wire: Wednesday, September 8, 2010
    Brad Meikle- 8 September 2010

    Editor’s Note: Today’s guest column comes from Randy Schwimmer of mid-market lender Churchill Financial.

  • peHUB Wire: Wednesday, September 8, 2010
    Brad Meikle- 8 September 2010

    Editor’s Note: Today’s guest column comes from Randy Schwimmer of mid-market lender Churchill Financial.